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ABSTRACT  
Objectives: Electroconvulsive therapy (ECT) is the most effective treatment for severe 
depression.  Previous efficacy studies, using thrice-weekly brief-pulse ECT, reported that high-
dose (6x seizure threshold) right unilateral ECT is similar to bitemporal ECT but may have 
fewer cognitive side-effects. We aimed to assess the effectiveness and cognitive side-effects of 
twice-weekly moderate-dose (1.5x seizure threshold) bitemporal ECT with high-dose unilateral 
ECT in real-world practice. 
 
Method: This was a pragmatic, patient- and rater-blinded, non-inferiority trial of patients 
with major depression (n=138; 63% female; age=56.7[SD=14.8]) in a national ECT service 
with a six-month follow-up. Participants were independently randomised to bitemporal or high-
dose unilateral ECT. The primary outcome was change in the 24-item Hamilton Depression 
Rating Scale (HAM-D24) after the ECT course; pre-specified non-inferiority margin was 4.0 
points. Secondary outcomes included response and remission rates, relapse status after six-
months, and cognition.   
 
Results: Sixty-nine patients were assigned to bitemporal ECT and 69 to unilateral 
ECT. High-dose unilateral ECT was non-inferior to bitemporal ECT regarding HAM-D24 after 
the ECT course (mean difference=1.2 points in favour of unilateral ECT [95% CI, -1·510 to 
3·995]). There were no significant differences for response and remission or six-month relapse 
status. Recovery-of-orientation was quicker following unilateral ECT (median 19·1 vs 26·4 
mins, p<0·001). Unilateral ECT was associated with better % recall of autobiographical 
information (OR=0·66, p=0·001) that persisted for six months.   
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Conclusions:  Twice-weekly high-dose unilateral ECT is not inferior to bitemporal ECT for 
depression, and may be preferable because of its better cognitive side-effect profile. 
 
Trial registration: Current Controlled Trials ISRCTN23577151. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 4 of 40The American Journal of Psychiatry
Peer Review Only
5 
 
INTRODUCTION 
Electroconvulsive therapy (ECT) is used to treat severe mental disorders in 1.4 million people 
annually worldwide, depression being the most common indication in Western countries (1). 
ECT is the most acutely effective treatment for treatment-resistant, sometimes life-threatening, 
depression (2, 3). Nevertheless, its use remains limited, mainly because of cognitive side-
effects (4), especially concerns about retrograde amnesia (5, 6).  
 Research on electrode placement has focused on preserving efficacy and minimising 
side-effects. Based on dosage, right unilateral ECT is less effective than bitemporal ECT (2), 
the most commonly used electrode placement worldwide (1), but causes less cognitive deficits 
(7). High-dose is more effective than low-dose ECT but more adversely affects memory (2, 7).  
However, recent efficacy trials (8-13) have demonstrated that unilateral ECT can be as 
effective as bitemporal ECT if delivered in high doses at multiples (e.g. 5-8x) of seizure 
threshold, the minimum charge required to induce the generalised seizure needed for 
therapeutic effect.  
 Although unilateral ECT causes fewer cognitive side-effects, the higher charges 
required to achieve comparable antidepressant efficacy might diminish its cognitive advantage. 
Relevant trials of brief-pulse (i.e. 1.0-1.5 msec pulse width) ECT have obtained inconsistent 
results: some show comparable cognitive performance following high-dose (5-8xthreshold) 
unilateral ECT with reference to moderate-dose (1.0-1.5xthreshold) bitemporal ECT (9, 10, 13) 
while others demonstrate less cognitive decline following high-dose (6xthreshold) unilateral 
ECT (8, 11, 12), although the latter studies mostly compared it with higher dose 
(2.5xthreshold) bitemporal ECT that increases cognitive side-effects (7). None of these studies 
was designed to determine unilateral non-inferiority for antidepressant effect and most had 
very limited follow-up. All used thrice-weekly treatment, common practice in the USA where 
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most of these trials originated, even though this does not result in better outcomes than twice-
weekly ECT (14) but is associated with increased cognitive side-effects (15). This limits their 
generalisability for populations where twice-weekly frequency is common practice, as occurs 
in many European countries, e.g. Belgium, Ireland, The Netherlands, UK (16, 17). 
Additionally, none of the previous trials reflected routine practice in that antidepressants were 
stopped before ECT and all but one (9) required receiving at least eight ECT sessions unless 
response criteria were met. 
 To date, no randomised trial has tested whether twice-weekly high-dose (6xthreshold) 
unilateral ECT is non-inferior to reference (1.5xthreshold) bitemporal ECT nor evaluated its 
superiority in terms of cognition and retrograde memory preservation over a prolonged follow-
up period. We aimed to examine short and long-term effectiveness and cognitive side-effects of 
high-dose unilateral ECT compared with bitemporal ECT for severe depression in routine 
practice over six-months.   
  
METHOD 
Study design and participants  
EFFECT-Dep was a pragmatic, patient- and rater-blinded, two-group, parallel, randomised, 
non-inferiority trial, with six-month follow-up (18, 19). Participants were all in-patients 
recruited between May 2008 and October 2012 from St. Patrick’s Mental Health Services 
(http://www.stpatricks.ie/), an independent non-profit organisation that provides national 
services and runs Ireland’s largest ECT clinic, including referrals from public-sector hospitals. 
Eligible participants were ≥18 years, referred for ECT, met diagnostic criteria for major 
depressive episode (unipolar or bipolar; Structured Clinical Interview for DSM-IV (20)) and 
scored ≥21 on the Hamilton Depression Rating Scale-24 (HAM-D24) (21). Exclusion criteria 
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were: conditions rendering patients unfit for general anaesthesia or ECT; ECT in previous six-
months; history of schizophrenia, schizoaffective disorder, neurodegenerative or other 
neurological disorder; alcohol/substance abuse in previous six-months; involuntary status; 
inability/refusal to consent. Treatment during the follow-up period was determined by patients 
in consultation with treating clinicians.  This study was approved by the hospital’s Research 
Ethics Committee (012/07) and written informed consent obtained after procedures were fully 
explained. 
 
Randomisation and masking 
After baseline assessments and before the first ECT session, patients were allocated (1:1) to 
bitemporal or unilateral ECT using an online system by the Clinical Trials Unit, King’s College 
London. Minimisation with variable block sizes ensured group allocation was balanced 
regarding three stratifiers: age>65 (yes/no); previous ECT (yes/no); referral site (St Patrick’s 
Mental Health Services/St James’s Hospital/other hospital).  Recruiting researchers 
electronically submitted participants’ identifying number, initials, birthdate, history of ECT, 
and referral site. Treating clinicians received e-mail notification of randomisation but were not 
involved in outcome assessments. Allocation was concealed from patients (prepared for 
receiving both electrode placements), recovery staff, referring clinicians, assessors and trial 
statistician until completion of final analyses. Success of masking was investigated after end-
of-treatment assessments by asking patients and raters to guess the treatment used. 
 
Interventions 
Brief-pulse (1.0 msec pulse width; current amplitude 800 mA) ECT was administered twice-
weekly (Mecta 5000M device, Mecta Corporation, USA; maximum 1200mC) according to 
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Royal College of Psychiatrists’ guidelines; using methohexital (0.75–1.0 mg/kg) anaesthesia 
and succinylcholine (0.5–1.0 mg/kg) for muscle relaxation (16, 22). Seizure threshold was 
established by dose titration at the first session (see Supplemental Material). Subsequent 
treatments were 1.5xthreshold for bitemporal and 6xthreshold for unilateral (d’Elia placement) 
ECT. Stimulus charge was titrated upwards as required during the treatment course (22, 23). In 
line with regular practice, the number of ECT sessions was determined by referring clinicians 
in consultation with patients, up to 12 sessions in accordance with recommendations of the 
Irish Mental Health Commission 
(http://www.mhcirl.ie/Mental_Health_Act_2001/Mental_Health_Commission_Codes_of_Pract
ice/Use_of_ECT_for_Voluntary_Patients/) who publish annual national data on ECT 
(http://www.mhcirl.ie/Publications/Publications/). Patients continued regular antidepressant 
treatments. ECT characteristics were recorded: seizure threshold (millicoulomb [mC]); mean 
stimulus charge (mC) for all sessions and non-titration sessions; motor and EEG seizure 
durations (seconds); total number of sessions; number of sessions to establish threshold. Time 
to recovery-of-orientation, i.e. ability to answer 4/5 simple orientation questions (person, place, 
age, birthdate, day) once breathing spontaneously post-ECT, was recorded after each 
session(24). 
 Common adverse physical effects (nausea, headache, muscle aches) were recorded for 
each session to measure occurrence (Yes/No) within each course.  Serious adverse events that 
required prolonged medical attention or were life-threatening were recorded. 
 Data were obtained at baseline, within, and soon after (2-4 days) completing the ECT 
course, and during six-month follow-up.  Baseline assessments included the National Adult 
Reading Test (premorbid IQ), and collection of demographic (age, gender, years-in-education, 
socio-economic and marital status) and clinical variables: referral reason, treatment-resistance 
(yes/no; Antidepressant Treatment History Form (25)), current psychotropic medications, 
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number of previous depressive episodes, current episode duration, presence of psychosis, 
depression polarity. Baseline Clinical Global Impression (CGI)-severity was rated by referring 
clinicians. 
 
Primary outcome 
The primary outcome was depression severity measured by HAM-D24 after completing the 
ECT course (end-of-treatment). Inter-rater reliability for HAMD-24 scoring was assessed every 
six-months; median intraclass correlation agreement was 0.96 (range 0.89-0.98). To classify 
depression status, HAMD-24 scores were obtained after every second ECT session and one-
week after the final session if indicated. 
 
Secondary outcomes 
Secondary depression outcomes included HAM-D24 scores at three- and six-month follow-
ups; end-of-treatment remission and response status; and relapse status for remitters during six-
month follow-up. Remission was defined as ≥60% decrease from baseline HAM-D24 and 
score ≤10 for two consecutive weeks; response as ≥60% decrease from baseline HAM-D24 and 
score ≤16; and relapse as HAM-D24 ≥16 for two consecutive weeks. The majority of patients 
who relapse following successful ECT do so within three-months (26).  To monitor relapse, 
HAM-D24 scores were obtained after end-of-treatment at: 2, 4, 6 and 8 weeks plus 3, 4 and 6 
months. 
 The post-ECT cognitive secondary outcome of main interest, retrograde amnesia 
measured by the Columbia University Autobiographical Memory Interview-Short Form (27), 
was prioritised for data collection. Further non-prioritised cognitive outcomes are summarised 
in Table S2 and included standardised measures of: global cognition (Mini-Mental State 
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Examination, MMSE); auditory attention and verbal working memory (Digit Spans Forward 
and Backward); psychomotor speed and executive function (Trail Making Tests A and B); 
semantic memory (category fluency); verbal learning and delayed recall (Free and Cued 
Selective Reminding Test); and visuo-spatial functioning and memory (Complex Figures 
Tests).  Alternative versions were used where appropriate. Cognitive outcomes were collected 
at baseline, end-of-treatment, and three- and six-month follow-ups. These outcomes, as well as 
the HAM-D24, were similar to ones used to establish efficacy and side-effects of bitemporal 
ECT (7, 8, 11-13, 16).  
 Subjective symptoms attributable to ECT were assessed with the Columbia ECT 
Subjective Side-Effects Schedule, including six items on memory, concentration and 
orientation for self-rating of cognition (total=18)(28).   
 
Sample size  
Based on a large bitemporal ECT series (29), we estimated 69 patients were required per group 
to have 80% power to demonstrate, using a one-sided equivalence t-test at 5% level, that the 
mean reduction in HAM-D24 following high-dose unilateral ECT was no more than 4-points 
(i.e. equivalent to 3-points on HAM-D17, deemed to be clinically relevant (30)) less that 
achieved using bitemporal ECT.   
 
Statistical analyses 
Analyses were on the intention-to-treat principle. ECT measures were summarised by trial arm 
using relevant descriptive statistics, accompanied by tests of zero group difference where this 
was not known a priori. We formally compared total numbers of sessions, numbers of sessions 
to establish seizure threshold (coded “1” or “≥2” sessions) and time to recovery-of-orientation 
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using regression, logistic regression and regression of log-transformed times respectively. In 
these regression models, randomisation stratifiers were included as explanatory variables in 
addition to trial arm. 
 The primary statistical analysis was assessment of difference in HAM-D24 scores 
between arms at end-of-treatment. The estimated group difference was supplemented by 95% 
confidence intervals and this interval compared to the non-inferiority threshold (4 points). A 
regression model was fitted to end-of-treatment HAMD-24 measures with pre-randomization 
HAMD-24, trial arm (unilateral/bitemporal) and randomisation stratifiers as covariates. A 
similar analysis model was assumed for secondary HAM-D24 outcomes at three- and six-
months follow-up. Within remitters, relapse during six-month follow-up was compared 
between arms using logistic regression as above. 
 The main secondary cognitive outcomes of interest – Autobiographical Memory 
Interview at end-of-treatment, three- and six-month follow-ups – were analysed using 
generalised linear models with a binomial distribution and logit-link (31). Post-treatment 
Autobiographical Memory Interview measures provide the number of baseline items recalled 
after ECT (27); such “number of items recalled” variables were therefore modelled as arising 
from binomial distributions, with maximum number of possible recalls set to the number of 
items obtained at baseline. An overdispersion parameter was introduced to account for recall of 
individual events being driven by subject characteristics. The covariates of these models were 
trial arm and randomisation stratifiers. 
 Similar regression models were employed to describe non-prioritised continuous 
secondary outcomes – other cognitive tasks and subjective side-effects (now also including 
baseline values as covariate). Time outcomes (i.e. Trails A and B) were log-transformed before 
analysis to acknowledge positively-skewed distributions. The same approach was applied for 
count outcomes displaying positive skewness (Subjective Side-Effects total and cognitive 
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scores). Group effects for these outcomes were therefore quantified by the ratio of outcome in 
the bitemporal arm to that in the unilateral arm. 
 For physical-safety analyses, we assessed proportions of patients who had adverse 
events by treatment-group and compared proportions using logistic regression modelling as for 
ECT measures. 
 Handling of missing data is described in Supplemental Material. We used Stata 
(version 13) and SPSS 19.0 (IBM Corp, NY) for statistical analyses.   
 
RESULTS  
Participant flow 
Figure 1 here 
 
Figure 1 shows the trial profile. 475 patients (mean age 62[SD=15.1]; 67.7% female) were 
referred for ECT during the recruitment period (May 2008 to October 2012), accounting for 
32.9% of all ECT referrals in Ireland (n=1480; average age=57.3; 66.5% female). 70 patients, 
all white Irish, were assigned per group. One patient per trial arm was excluded post-
randomisation because they were found not to fulfil eligibility criteria. Comparing the 138 
participants to the 113 potentially eligible non-participants, participants were younger (56.7[SD 
14.8] vs 63.4[SD 14.3] years; t=3.64, p=0.0001) but did not differ significantly regarding 
gender (% female: 63% vs 67%; chi-square test, p=0.52) or baseline CGI-severity (5.3[SD 0.7] 
vs 5.2[SD 0.9] (n=101); U-test z=0.93, p=0.35) and MMSE scores (27.7[SD 2.1] (n=119) vs 
27.8[SD 2.5] (n=85); t=-0.27, p=0.79). 
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 All patients adhered to allocated treatment, although five (7.2%) unilateral patients 
had thresholds >200mC (225mC, N=1; 250mC, N=3; 500mC, N=1) and so could not be treated 
at fully 6xthreshold. Nearly all participants (N=136; 98.6%) were assessed for primary 
outcome at end-of-treatment while 82% and 76% were followed-up respectively at three- and 
six-months.  
 Treatment guesses were made by patients (119/138) and raters (118/138): 12 patients 
couldn’t guess; 26/56 of the unilateral group and 36/51 in bitemporal group correctly guessed 
(χ2=3.27, p=0.07, Kappa=0.17 (low coefficient of beyond-chance agreement)). For raters, 
30/57 of guesses for the unilateral group and 36/61 for bitemporal group were correct (χ2=1.61, 
p=0.21, Kappa=0.12). Thus masking was successful for patients and raters. 
 
Baseline and treatment characteristics    
Summaries of baseline characteristics were comparable between trial arms as would be 
expected under random allocation (Table 1). Age (56.7[14.8] years), gender (63% female), 
psychosis-status (21%), bipolarity (23%), baseline HAM-D24 (29.9[6.2]), and depression 
episode median duration (19.5 weeks) for total sample were similar to previous relevant trials 
(8, 9, 11-13) and large observational studies (5, 29).  
 
Tables 1 and 2 here 
 
 Anaesthesia doses were similar for the two groups (Table 2).  In line with previous 
studies (8-12), we found threshold was lower with unilateral ECT, total stimulus charges were 
higher in the unilateral group, while seizure durations were similar between groups.  93% of 
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patients had an adequate seizure in the first session. Although it took fewer sessions to 
establish threshold in the unilateral group (p=0.002), there was no significant difference 
between groups for total number of ECT sessions (p=0.26). Median time to recovery-of-
orientation following the initial titration-session in the unilateral group was half that of 
bitemporal group (p<0.001) and this cognitive advantage was maintained, though to a lesser 
extent, during remainder of the course. 
 
Primary and secondary mood outcomes 
Figure 2 here 
 
High-dose unilateral ECT was non-inferior to bitemporal ECT at end-of-treatment.  Changes in 
HAM-D24 scores are illustrated in Figure 2a. The pre-specified non-inferiority margin was no 
more than -4 points difference at end-of-treatment between bitemporal and unilateral groups 
(Figure 2b). The predicted difference at end-of-treatment was 1.08 (95% CI -1.67 to 3.84; 
unilateral N=67, bitemporal N=69). Non-inferiority was evident at both three-month (3.48, 
95% CI -0.046 to 7.0; unilateral N=60, bitemporal N=53) and six-month (0.26, 95% CI -3.33 to 
3.85; unilateral N=55, bitemporal N=50) follow-ups.  
 These results translated into similar proportions of responders (unilateral: 42/69 
(60.8%); bitemporal: 35/69 (50.7%)) and remitters (unilateral: 32/69 (46.4%); bitemporal: 
29/69 (42.0%)) in the two groups at end-of-treatment. The median number of ECT sessions for 
both responders and remitters was 7 (range 3-12) and was less than for both non-responders 
and non-remitters at 9 (range 3-12) (for both Mann-Whitney U test, p<0.001).  During the six-
month follow-up there was no significant difference between proportions of remitters who 
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relapsed in the unilateral (8/32; 25.0%) and bitemporal (11/29; 37.9%) groups (OR 
(unilateral/bitemporal)=0.56, 95% CI 0.17 to 1.79, z=0.99, p=0.32). 
 
Cognitive secondary outcomes 
Figure 3 here 
 
The cognitive outcome of main interest post-ECT was retrograde amnesia as measured by 
Autobiographical Memory Interview. Autobiographical memory scores for unilateral 
(46.9[9.7], N=66) and bitemporal (44.4[10.3], N=64) groups were similar at baseline.  The % 
consistency of recall of  baseline memories was lower in the bitemporal group at end-of-
treatment (OR=0.66, 95% CI 0.513 to 0.85, p=0.001; unilateral N=64, bitemporal N=64) and 
this was maintained at follow-up after three-months (OR=0.59, 95% CI 0.45 to 0.78, p<0.001; 
unilateral N=56, bitemporal N=48) and six-months (OR=0.59, 95% CI 0.45 to 0.79, p<0.001; 
unilateral N=49, bitemporal N=42) (Figure 3). Distributions of individual % recall 
consistencies are presented in Table S3. 
 Assessment completion levels varied for non-prioritised secondary outcomes. End-of-
treatment completion rates ranged from 93.5% (category fluency) to 71.7% (verbal learning). 
Three-month completion rates varied from 62.3% (category fluency) to 47.8% (Trail-Making 
B), and at six-months from 59.4% (category fluency) to 42.8% (Trail-Making B).   
 There were few differences between groups for the other cognitive tasks (Table S4).  
At end-of-treatment the only statistically significant difference was for better performance in 
the unilateral group on verbal learning for immediate recall (p=0.034) though not delayed 
recall (p=0.22).  There were no differences between groups on these verbal learning and 
memory tasks at three- and six-month follow-ups.  At three-months performance was better in 
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the unilateral group for both auditory attention (p=0.021) and verbal working memory 
(p=0.049) but these cognitive advantages were not evident at end-of-treatment or six-month 
follow-up. 
 There were no significant differences between groups on the Subjective Side-Effects 
Schedule for total side-effects at any timepoint (Table S4) although number and severity of 
side-effects declined substantially over time, probably in line with improved mood (16, 28). 
However, significantly fewer subjective cognitive side-effects were reported by the unilateral 
group at end-of-treatment (p=0.02) and after six-months (p=0.025).  Thus there were both 
objective and subjective cognitive advantages for unilateral compared to bitemporal ECT. 
 
Adverse events 
There were no differences between unilateral and bitemporal groups for occurrence of 
headaches (26.5% vs 27.5%; OR=0.93, 95% CI 0.42 to 2.04; z=0.20, p=0.84), nausea (16.2% 
vs 11.6%; OR=1.54, 95% CI 0.56 to 4.17; z=-0.84, p=0.40) or muscle pain (11.8% vs 8.7%; 
OR=1.37, 95% CI 0.44 to 4.17; z=-0.55, p=0.58). 
 Regarding major adverse events, six patients required β-blockers for ECT-related 
hypertension (unilateral N=4, bitemporal N=2). In the unilateral group: one patient developed 
laryngospasm with temporary drop in oxygen saturation; one developed tachyarrhythmia 
necessitating ECT termination; and one attempted suicide during the course. In the bitemporal 
group: three developed inter-ictal confusion resulting in postponement/termination of ECT; one 
developed bronchospasm; one required β-blocker for sinus tachycardia; one developed 
bradyarrhythmia; and one developed a pulmonary embolus after the fifth treatment. None of 
these events led to trial dropout. 
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DISCUSSION 
Our findings show that twice-weekly high-dose unilateral ECT is non-inferior to bitemporal 
ECT for severe depression in regular clinical practice, which included continued antidepressant 
pharmacotherapy, and this was maintained over six-months. The proportions of responders and 
remitters, as well as relapse rates, are consistent with this. Furthermore, we found high-dose 
unilateral ECT to be less taxing on autobiographical memory than bitemporal ECT. The 
unilateral group showed significantly higher autobiographical memory consistency with 
baseline recall than the bitemporal group at end-of-treatment, and three- and six-month follow-
ups. Other cognitive advantages of unilateral ECT included quicker recovery-of-orientation 
following treatments, better verbal learning at end-of-treatment, and fewer subjective cognitive 
side-effects. Both forms of ECT were well-tolerated. Numbers of common physical side-effects 
and serious adverse events were similar in both groups, in line with previous studies reporting 
harms (12, 32).    
 Our findings for the primary outcome, HAM-D24, are consistent with results of 
previous, non-pragmatic, thrice-weekly efficacy trials (8-13). However, the overall remission 
rate (44.2%) was lower than in some trials (range 46-65%) (8, 9, 11-13) but similar to that in a 
large community study (46.7%) (33) while the overall six-month relapse rate (31.1%) was at 
the lower limit reported in a recent meta-analysis of post-ECT relapse (26). These differences 
most likely reflect the pragmatic nature of our trial, where number of treatments was decided 
by patients and referring physicians rather than by protocol as well as a naturalistic follow-up, 
and are unlikely to be related to concomitant use of antidepressants, which may improve ECT 
efficacy (12).  Cognitive outcomes at end-of-treatment were consistent with previous thrice-
weekly ECT trials (8, 9, 11, 12). Regarding autobiographical memory, as measured by the 
Autobiographical Memory Interview, our findings differed only from two previous trials (9, 
13) that found both treatments had comparable effects. This might be explained by the higher 
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stimulus charge used for the unilateral group (8xthreshold) for one trial (9) and/or use of thrice-
weekly ECT (9, 13) as both result in larger cognitive deficits.  
 
Strengths and weaknesses 
Trial strengths include non-inferiority design, pragmatic attitude, relatively large sample size 
and adequate power.  We showed excellent adherence and end-of-treatment completion rates. 
Retention at both follow-ups was satisfactory for the primary and main cognitive outcomes and 
superior to previous relevant trials. Indeed, existing efficacy trials either lacked follow-up (8, 
12, 13), had shorter follow-ups (1-2 months) (9, 10) and/or had smaller follow-up samples (19-
22 per group) (9, 11). None was designed to test non-inferiority of high-dose unilateral ECT 
compared to bitemporal ECT. The randomised sample was representative of the general 
population referred for ECT and similar to potentially eligible non-participants. Our findings, 
therefore, have good generalisability to countries where twice-weekly ECT is normal practice.  
 Our study has some limitations.  First, we did not include involuntary patients who 
could not consent due to illness severity (7.4% of referrals) for whom bitemporal ECT may be 
better(13).  Second, other than for autobiographical memory, there are high levels (13-54%) of 
missing variables for secondary cognitive outcomes at follow-ups. Nevertheless, this study 
presents the best available evidence of long-term cognitive correlates of high-dose unilateral 
and bitemporal ECT. A third limitation concerns the Autobiographical Memory Interview. We 
selected this instrument to situate our trial within existing research evidence as most previous 
trials used a variant of it (8, 11-13). However, it does not allow quantification of retrograde 
amnesia attributable directly to ECT even though it is sensitive in detecting differences 
between treatment allocations on autobiographical memory recall (6, 7, 34, 35). Nevertheless, 
the present trial shows that high-dose unilateral ECT affects autobiographical memory less than 
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bitemporal ECT. Fourth, all trial participants were in-patients but this reflected routine practice. 
Fifth, the relatively lower remission rate may be due to the pragmatic design when compared to 
other trials (8-13) performed under more stringent, but less clinically general, conditions. 
 
CONCLUSIONS 
Our study has important clinical implications.  In terms of harms/benefits ratio, high-dose 
unilateral ECT is non-inferior to bitemporal ECT but showed a better cognitive profile, 
especially for preserving retrograde personal memories and fewer subjective cognitive side-
effects. While there is much interest in other modifications to maintain effectiveness but reduce 
side-effects, e.g. ultrabrief pulse-width ECT, these require further refinement and 
characterization for optimisation (36, 37). Our findings justify considering high-dose unilateral 
ECT as the preferred ECT option for treating depression and may help improve acceptability 
and availability of this effective treatment. 
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FIGURE LEGENDS 
 
Figure 1: Trial profile  
HAM-D24=Hamilton Depression Rating Scale-24 item version. ECT=electroconvulsive 
therapy. SCID-IV=Structured Clinical Interview for DSM-IV. RUL=right unilateral. 
 
Figure 2: Intention-to-treat analyses of primary outcome 
(a) Predicted mean HAM-D24 (95% CI) scores for the unilateral and bitemporal ECT groups at 
end-of-treatment plus three-month and six-month follow-ups. Means are predicted for patients 
with average baseline outcome value, who are of younger age (≤65 years), referred from St. 
Patrick’s Mental Health Services and have no previous experience of ECT. All analyses were 
carried out using multiple imputation with 200 imputations (see Statistical Analysis and 
Supplemental Data). All models used to construct inferences were adjusted for baseline HAM-
D24 scores and conditioned on stratifiers. (b) The dashed line is the pre-defined non-inferiority 
margin (-4 points on the HAM-D24).  The green line shows the predicted mean (95% CI) 
differences in HAM-D24 scores at the same time points as in (a). HAM-D24=Hamilton 
Depression Rating Scale-24 item version. RUL = right unilateral ECT. Bitemp = bitemporal 
ECT. EoT=end-of-treatment. M=months. 
 
Figure 3: Autobiographical memory following ECT: recall consistency (%) with baseline 
scores for unilateral and bitemporal ECT groups  
CAMI-SF=Columbia Autobiographical Memory Interview-Short Form. EOT=end-of-
treatment. M=months. 
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TABLE 1: Baseline clinical and demographic characteristics
a
 
Characteristic Total sample 
(N=138) 
Right unilateral 
ECT 
(N=69) 
Bitemporal ECT 
(N=69) 
 Mean SD Mean SD Mean SD 
       
Age (years) 56.7 14.8 56.6 15.3 56.8 14.4 
Education (years) 13.1 3.4 13.7 3.0 12.6 3.8 
HAM-D24 29.9 6.2 30.4 6.1 29.5 6.3 
MMSE
a,b
 27.7 2.1 28.0 1.8 27.4 2.4 
National Adult Reading Test
a,c
 108.3 6.8 109.2 5.6 107.4 7.8 
CGI-S
d 
5.3 0.7 5.4 0.7 5.3 0.7 
Number of psychotropic medications 4.2 1.4 4.3 1.3 4.2 1.5 
 Median Range Median Range Median Range 
Episode duration
e
   19.5 2-104 18.0 4-104 21.0 2-104 
Number of previous episodes 4.0 0-23 4.0 0-20 3.0 1-23 
 N % N % N % 
Female gender 87 63.0 40 58.0 47 68.1 
Socio-economic group       
       Professional 24 17.4 10 14.5 14 20.3 
       Managerial or technical 23 16.7 15 21.7 8 11.6 
       Skilled occupations 36 26.1 23 33.3 13 18.8 
       Partly skilled occupations 22 15.9 8 11.6 14 20.3 
       Unskilled occupations 31 22.5 11 15.9 20 29.0 
       Not specified 2 1.4 2 2.9 0 0.0 
Marital status       
       Married 76 55.1 38 55.1 38 55.1 
       Single 35 25.4 17 24.6 18 26.1 
       Widowed/divorced 25 18.1 12 17.4 13 18.8 
       Not specified 2 1.4 2 2.9 0 0.0 
Bipolar depression 32 23.2 16 23.2 16 23.2 
Presence of psychosis 29 21.0 16 23.2 13 18.8 
Treatment resistance
f
 99 72.8 45 66.2 54 79.4 
History of previous ECT 53 38.4 26 37.7 27 39.1 
Primary reason for ECT referral
d
       
      Refractory to medication 75 54.3 37 53.6 38 55.1 
      Rapid response required 57 41.3 29 42.0 28 40.1 
      Acute suicidality 5 3.6 2 2.9 3 4.3 
      Physical deterioration 1 0.7 1 1.4 0 0.0 
Psychotropic medications       
      SSRIs 29 21.0 15 21.7 14 20.3 
      SNRIs 67 48.6 32 46.4 35 50.7 
      Tricyclic antidepressants 39 28.3 20 29.0 19 27.5 
      Tetracyclic antidepressants 6 4.3 6 8.7 0 0.0 
      Mirtazapine 46 33.3 24 34.8 22 31.9 
      Agomelatine 2 1.4 1 1.4 1 1.4 
      Lithium 56 40.6 28 40.6 28 40.6 
      Anticonvulsants
g
 39 28.3 18 26.1 21 30.4 
      Benzodiazepines 81 58.7 35 50.7 46 66.7 
      Antipsychotics 97 70.3 48 69.6 49 71.0 
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      Z-hypnotics 69 50.0 34 49.3 35 50.7 
      Tryptophan 2 1.4 1 1.4 1 1.4 
      Buproprion 4 2.9 2 2.9 2 2.9 
      MAOI 1 0.7 0 0.0 1 1.4 
      Buspirone 1 0.7 0 0.0 1 1.4 
       
Data are mean (SD) or N (%), unless otherwise indicated. 
a
Data not available for all participants. 
b
N=119 (59 right unilateral, 60 bitemporal) 
c
N=112 (54 right-unilateral, 58 bitemporal) 
d
As recorded by referring physician.  
e
Capped at 104 weeks. 
 
f
Treatment resistance was based on the Antidepressant Treatment History Form, N=136. 
g
Anticonvulsants include lamotrigine, sodium valproate and pregabalin prescribed as mood stabilisers or 
anxiolytic. 
HAM-D24=24-item Hamilton Depression Rating Scale. MMSE=Mini-Mental State Examination. CGI-S=Clinical 
Global Impression-Severity Scale.  SSRIs=Selective serotonin reuptake inhibitors. SNRIs= Serotonin and 
Noradrenaline Reuptake Inhibitors. MAOI=Monoamine Oxidase Inhibitor. 
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TABLE 2: ECT session measures 
 Right unilateral ECT
a
 
(N=69) 
Bitemporal ECT 
(N=69) 
Formal test
b
 
 Mean SD Mean SD  
ECT treatment characteristics      
Anaesthesia
c
      
       Methohexitone (mg/kg) 1.1 0.2 1.0 0.2 NA 
       Suxamethonium (mg/kg) 0.8 0.2 0.8 0.2 NA 
Stimulus charge (mC), all sessions 620.3 223.5 368.1 192.0 NA 
Stimulus charge (mC), non-titration 
sessions
d
 
741.6 275.6 403.5 207.6 NA 
Total number of sessions 7.8 2.5 8.3 2.4 t(131)=1.13, 
p=0.26 
 Median Range Median Range  
Initial seizure threshold (mC) 75 50-500 150 50-500 NA 
Motor seizure duration (s) 28 12-55 28 14-63 NA 
EEG seizure duration 42 17-87 40 16-116 NA 
 Percentage (%)  
Number of sessions to establish the 
seizure threshold 
   
       1 session 81 56 z=3.07, 
p=0.002        2 sessions 18 41 
       3 sessions 1 3 
      
 Median Range Median Range  
Recovery of orientation
e
       
Time to recovery (mins), initial 
titration session 
10 5-60 20 5-60 t(130)=6.82, 
p<0·001
f
 
Time to recovery (mins), non-titration 
sessions
g
 
19.1 10-55 26.4 10-60 t(130)=3.88, 
p<0·001
f 
      
Data are mean (SD), unless otherwise indicated. 
a
Data not available for all participants (N=67-68). 
b
All models used to construct inferences were conditioned on stratifiers. 
c
Six patients received propofol during their ECT course at standard doses due to temporary shortage of 
methohexital, four in the bitemporal group and two in the unilateral group. 
d
A mean time was estimated for all sessions following the definite establishment of the seizure threshold. 
e
Recovery of orientation was defined as correctly answering 4/5 reorientation questions. 
f
Formal inferences carried out after log-transformation. 
g
A mean time was estimated for all sessions following the definite establishment of the seizure threshold. 
NA=not attempted. mC=millicoulombs. EEG=electroencephalogram. 
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Included in analysis (N=69) Included in analysis (N=69) 
Assigned to RUL ECT (N=70) 
Followed-up at 3 months 
Excluded (N=222) 
• Involuntary status (N=35) 
• Already in trial (N=32) 
• HAM-D24 score <21 (N=29) 
• Voluntary but lacked capacity (N=29) 
• ECT in last 6 months (N=28) 
• Other Axis 1 disorder (N=24) 
• Substance abuse in last 6 months 
N=15)  
• Cognitive impairment (N=12) 
• Did not meet SCID-IV criteria (N=11) 
Referred to specific laterality (N=7) 
Randomly assigned 
Assessed for eligibility (N=475) 
Refused participation (N=103) 
Unable to participate due to                        
organisational reasons (N=10) 
• Excluded post randomisation 
(pre-existing neurological    
disorder) (N=1) 
• Withdrew from study (N=2) 
• Excluded post randomisation 
     (altered diagnosis) (N=1) 
Assigned to bitemporal ECT 
(N=70) 
Patients approached 
to participate (N=253) 
Followed-up at EOT (N=67) Followed-up at EOT (N=69)  
Followed-up at 6 months 
(N=55) 
Followed-up at 3 months 
Followed-up at 6 months 
(N=50) 
• Withdrew from study (N=2)     
• Refused 3-month assessment (N=5) 
• Withdrew from study (N=7)     
• Refused 3-month assessment (N=1) 
• Researcher unable to contact (N=8) 
 
• Withdrew from study (N=2)     
• Refused 6-month assessment (N=7) 
• Researcher unable to contact (N=1) 
 
• Withdrew from study (N=3)     
• Refused 6-month assessment (N=1) 
• Researcher unable to contact (N=7)   
• Died (N=1) 
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Bitemporal versus high-dose unilateral twice-weekly electroconvulsive therapy 
for depression (EFFECT-Dep): a pragmatic, randomised, non-inferiority trial 
 
Supplemental Material 
 
 
ECT DOSING PROCEDURES 
Brief-pulse (1.0 msec pulse width; current amplitude 800 mA) ECT was administered with 
hand-held electrodes using the Mecta 5000M device (Mecta Corporation, USA; maximum 
1200mC).  Methohexital (0.75–1.0 mg/kg) was used for anaesthesia and succinylcholine 
(0.5–1.0 mg/kg) for muscle relaxation. Patients were oxygenated during the procedure with 
100% O2 under positive pressure and were monitored for blood pressure, heart rate and 
rhythm, pulse oximetry and capnography.  Seizure duration was measured by observation of 
motor activity and electroencephalogram (EEG).   
Table S1 Stimulus titration and dosing procedures 
  Suprathreshold treatment dose (mC) 
Level Threshold (mC) Bitemporal (1.5x) Right unilateral (6x) 
1 25 50 150 
2 50 75 300 
3 75 125 450 
4 100 150 600 
5 150 225 900 
6 250 375 1200 
7 350 550 1200 
8 500 750 1200 
9 750 1000 1200 
 
 Empirical dose titration was used to establish the seizure threshold in the first ECT 
session (1, 2).  The seizure threshold was defined as the lowest stimulus charge that produced 
an adequate seizure, i.e. a generalised tonic/clonic seizure lasting ≥15 seconds from the end 
of the stimulus, or an electroencephalogram (EEG) record of polyspike followed by 3 Hz 
spike-and-wave activity lasting ≥25 seconds. The titration procedure is shown in Table S1 
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and began at the lowest dose of 25 mC.  Several factors are known to affect seizure threshold, 
including older age (>65 years), male gender, use of benzodiazepines and anticonvulsant 
drugs, and bitemporal electrode placement (3). The presence of any of these factors was 
incorporated into the dose titration algorithm to tailor the process to the individual patient by 
beginning at one level higher for each one of these factors when present. For example, in the 
titration procedure shown in Table S1, the initial stimulus dose for a young adult female 
undergoing unilateral ECT would be at the lowest level, i.e. 25 mC.  However, if she was 
over 65 years old and taking regular benzodiazepines, the initial stimulus dose would be 
increased by two levels up to 75 mC. 
 Patients were stimulated at the appropriate initial level.  If an adequate seizure was 
not produced, then the patient was restimulated one level higher (see Table S1). There was an 
interval of at least 30 seconds before each restimulation.  If an adequate seizure was still not 
produced after the second attempt, and anaesthetic conditions permitted, the patient was 
restimulated for the second time at another two levels higher, i.e. one level was skipped.  If in 
the first session a third stimulation was required and resulted in an adequate seizure, the 
seizure threshold could have been either the dose used or the previous (i.e. skipped) level.  
Therefore, the second session began with the skipped dose level to clarify the seizure 
threshold.  
 Once the seizure threshold was established, subsequent treatments were given at 
1.5xthreshold for bitemporal and 6xthreshold for unilateral (d’Elia placement) ECT.  Seizure 
threshold can substantially rise over the course of ECT and this may be manifested in a 
progressive shortening in seizure duration. The aim of the treatment is to ensure that the dose 
clearly remains suprathreshold (2).  Therefore, if the EEG seizure duration fell by >20% 
relative to the second session then the initial stimulus dose was raised in the next session by 
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one level (see Table S1).   This new level was adopted as the initial dose for subsequent 
sessions. 
 
HANDLING OF MISSING DATA 
In the presence of missing data, the resulting (maximum likelihood) estimators of group 
effects on outcome variables are valid provided that missing data-generating mechanisms are 
Missing At Random (MAR), which here implies that the probability of the outcome being 
unobserved at the respective post treatment time point depends only on covariates included in 
the analysis model. Such a MAR assumption might not be realistic and violations of the 
assumption could lead to biased effectiveness estimates, in particular for non-prioritised 
secondary outcomes. To base analyses on less restrictive MAR assumptions, we employed 
multiple imputation (MI).  This allowed us to include additional variables (including post 
randomisation variables) in the imputation step of the MI procedure without having to 
condition on them in the analysis model. The approach relaxed the MAR assumption to also 
allow these variables to be predictive of missing outcome and thus avoid bias (4). 
Specifically, the following types of variables were included in the imputation step: (i) 
outcome measures at all available time points; (ii) covariates of the analysis model; (iii) 
known prognostic variables (treatment resistance(5, 6), psychosis(7)); (iv) HDRS-24 at any 
time point since ability to complete questionnaires may be affected by current depression 
severity; (v) additional baseline variables detected empirically to predict missingness of 
respective 6-month outcomes (see later Results); (vi) CAMI-SF at end-of-treatment if this 
prioritised outcome was found to be predictive of any outcome missingness (8).   
 Regarding (v) and (vi), we ran a series of binary logistic regressions for observing 
values of HDRS-24, CAMI-SF, Trail-Making B and FCSRT immediate recall at six-months. 
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Poor end-of-treatment CAMI-SF performance predicted missingness of both HDRS-24 and 
CAMI-SF at six-months and was included in all imputation models. With regard to non-
prioritised outcomes, poorer performance on category fluency and better performance on 
FCSRT immediate recall at baseline predicted missingness respectively in Trail-Making B 
and FCSRT immediate recall and these two variables were also included in the imputation 
models for these outcomes. 
 Imputation by chained equations was carried out using Stata’s ice command with 
the number of imputations set to 200. Steps were taken to ensure imputed values lay within 
limited scale ranges and respected the discrete nature of some scales.  In addition, 
distributions of imputed values were always compared with those of respective observed 
values to check that imputed values appeared realistic. (Further technical information 
regarding imputation procedures can be requested from the authors.) Where missing values 
were present in an outcome we always report findings from the multiple imputation analysis. 
For the prioritised outcomes (HDRS-24, CAMI-SF), where the amount of missingness was 
relatively small, we also compared MI results with complete-case analysis results and found 
these to be very similar (details not reported.)   
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Table S2 Neurocognitive test battery and associated references 
Test Reference 
Mini-mental state examination Folstein MF, Folstein SE, McHugh PR: "Mini 
mental state": a practical method for grading 
the cognitive state of patients for the clinician. J 
Psychiatr Res 1975; 12:189-198 
National Adult Reading Test Nelson HE, Willison I: National Adult Reading 
Test (NART). Windsor, NFER Nelson, 1991 
Digit Span (WAIS-III) Wechsler D: Wechsler Adult Intelligence Scale-
Third Edition (WAIS-III). San Antonio, The 
Psychological Corporation, 1997 
Trails Making Tests A and B Reitan RM Wolfson, D: The Halstead–Reitan 
Neuropsycholgical Test Battery: Therapy and 
clinical interpretation. Tucson, AZ, 
Neuropsychological Press, 1985 
Category fluency  Lezak MD, Howieson DB, Biegler ED, Tranel D: 
Neuropsychological assessment. 5th ed. New 
York, Oxford Univerity Press, 2012 
Free and Cued Selective Reminding Test Van der Linden M, GREMEM: Memory 
disorders assessment - four episodic memory 
tests with normative data. Marseille, Solal, 
2004 
Complex Figures Test Strauss E, Sherman EMS, Spreen O: 
Compendium of Neuropsychological Tests: 
Administration, Norms, and Commentary. 3rd 
ed. New York, Oxford University Press, 2006, 
pp. 811-841 
Versions: (1) Rey-Osterrieth, Form A, (2) Rey-
Osterrieth, Form B, (3) Medical College of 
Georgia Complex Figure 1; (4) Medical College 
of Georgia Complex Figure 2 
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TABLE S3:  Distribution of % autobiographical memory recall consistency scores 
on the Columbia Autobiographical Memory Interview – Short Form according to 
treatment allocation 
 Bitemporal electrode 
placement 
Right unilateral electrode 
placement 
 End-of-treatment 
Minimum 0 27 
Maximum 100 93 
25
th
 Percentile 46.25 54.25 
50
th
  Percentile 55.00 71.00 
75
th
  Percentile 69.00 80.75 
 3-months follow-up 
Minimum 11 20 
Maximum 100 93 
25
th
 Percentile 41.50 59.25 
50
th
  Percentile 56.50 68.00 
75
th
  Percentile 67.75 76.75 
 6-months follow-up 
Minimum 28 13 
Maximum 95 92 
25
th
 Percentile 42.00 53.5 
50
th
  Percentile 50.00 65.00 
75
th
  Percentile 64.25 78.50 
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TABLE S4: Results of analyses of cognitive outcomes by post treatment time point 
Cognitive tasks 
 
 Comparison of randomisation groups
a
 
 Predicted 
mean
b
 
RUL 
(N=69) 
Predicted 
mean
b
 
Bitemporal 
(N=69) 
Estimated difference 
in means  
Statistical 
significance 
test 
 
BT-
RUL 
 
95% CI 
 
z 
 
p 
Global cognitive status: 
MMSE 
      
    Baseline (sample average) 27.7 (N=59) 27.7 (N=60)     
    EOT 27.8 (N=62) 27.4 (N=63) -0.4 -1.2 to 0.4 -0.93 0.35 
    3 months 27.9 (N=45) 28.1 (N=31) 0.2 -0.6 to 1.0 0.44 0.66 
    6 months 28.2 (N=38) 28.1 (N=32) -0.1 -1.1 to 1.0 -0.12 0.90 
Psychomotor speed:  
TMT-A
c
 
      
    Baseline (sample average) 51.4 (N=49) 51.4 (N=54)     
    EOT 53.1 (N=54) 47.9 (N=59) 0.9 0.8 to 1.0 -1.52 0.13 
    3 months 44.1 (N=40) 43.8 (N=28) 1.0 0.8 to 1.2 -0.07 0.94 
    6 months 41.0 (N=34) 43.1 (N=30) 1.1 0.9 to 1.3 0.52 0.61 
Auditory attention:  
Digit span forward 
      
    Baseline (sample average) 8.0 (N=53) 8.0 (N=52)     
    EOT 8.8 (N=55) 8.1 (N=58) -0.7 -1.5 to 0.2 -1.51 0.14 
    3 months 8.8 (N=41) 7.7 (N=30) -1.2 -2.1 to -0.2 -2.36 0.02 
    6 months 9.3 (N=38) 8.4 (N=29) -0.8 -1.8 to 0.1 -1.76 0.08 
Verbal working memory:  
Digit span backward 
      
    Baseline (sample average) 5.7 (N=53) 5.7 (N=52)     
    EOT 5.9 (N=55) 5.8 (N=58) -0.04 -0.9 to 0.8 0.08 0.93 
    3 months 6.4 (N=41) 5.6 (N=30) -0.8 -1.6 to 0.0 2.01 0.05 
    6 months 7.0 (N=37) 6.3 (N=29) -0.6 -1.7 to 0.5 -1.16 0.25 
Verbal learning:  
FCSRT immediate recall 
      
    Baseline (sample average) 24.9 (N=47) 24.9 (N=48)     
    EOT 25.7 (N=49) 22.5 (N=50) -3.2 -6.1 to -0.2 -2.15 0.03 
    3 months 27.3 (N=36) 26.7 (N=31) -0.6 -3.5 to 2.4 -0.40 0.69 
    6 months 28.5 (N=33) 27.6 (N=28) -0.9 -4.9 to 3.0 -0.46 0.65 
Verbal delayed memory: 
FCSRT delayed recall 
      
    Baseline (sample average) 9.6 (N=47) 9.6 (N=47)     
    EOT 8.5 (N=49) 7.7 (N=49) -0.8 -2.1 to 0.5 -1.24 0.22 
    3 months 9.3 (N=36) 9.2 (N=31) -0.2 -1.5 to 1.2 -0.23 0.82 
    6 months 9.6 (N=32) 9.2 (N=28) -0.4 -1.8 to 1.05 -0.53 0.60 
Visuo-spatial functioning:  
CFT copy 
      
    Baseline (sample average) 26.4 (N=46) 26.4 (N=45)     
    EOT 28.9 (N=51) 29.2 (N=54) 0.3 -1.4 to 2.1 0.37 0.71 
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    3 months 30.9 (N=39) 31.0 (N=31) 0.2 -1.5 to 1.8 0.19 0.85 
    6 months 30.3 (N=33) 30.2(N=29) -0.1 -1.8 to 1.6 -0.09 0.93 
Visual memory:  
CFT delayed recall 
      
    Baseline (sample average) 11.3 (N=44) 11.3 (N=40)     
    EOT 14.8 (N=50) 14.1 (N=49) -0.7 -2.9 to 1.5 -0.65 0.52 
    3 months 19.2 (N=39) 18.0 (N=28) -1.2 -3.9 to 1.5 -0.89 0.38 
    6 months 19.2 (N=32) 18.1 (N=28) -1.1 -4.1 to 2.0 -0.70 0.49 
Semantic memory:  
Category fluency 
      
    Baseline (sample average) 14.0 (N=60) 14.0 (N=59)     
    EOT 12.7 (N=65) 12.1 (N=64) -0.6 -2.3 to 1.0 -0.77 0.44 
    3 months 14.1 (N=53) 13.8 (N=33) -0.3 -2.3 to 1.8 -0.28 0.78 
    6 months 14.4 (N=46) 13.5 (N=36) -0.9 -2.8 to 1.0 -0.93 0.36 
Executive functioning:  
TMT-B
c
 
      
    Baseline (sample average) 117.9 (N=46) 117.9 (N=50)     
    EOT 103.8 (N=47) 107.7 (N=54) 1.0 0.9 to 1.2 0.42 0.67 
    3 months 87.0 (N=39) 93.1 (N=27) 1.1 0.9 to 1.3 0.66 0.51 
    6 months 84.1 (N=32) 97.2 (N=27) 1.2 0.9 to 1.5 1.16 0.25 
       
Total side-effects:   
CSSES total score
c
 
      
    Baseline (sample average) 22.4 (N=50) 22.4 (N=48)     
    EOT 14.2 (N=63) 17.3 (N=62) 1.2 0.9 to 1.6 1.44 0.15 
    3 months 12.5 (N=47) 13.4 (N=32) 1.1 0.7 to 1.6 0.38 0.71 
    6 months 8.7 (N=39) 12.1 (N=38) 1.4 0.9 to 2.1 1.49 0.14 
Cognitive side-effects:    
CSSES cognitive score
c
 
      
    Baseline (sample average) 5.0 (N=52) 5.0 (N=48)     
    EOT 3.8 (N=63) 5.5 (N=62) 1.4 1.1 to 2.0 2.32 0.02 
    3 months 4.2 N=47) 4.9 (N=32) 1.2 0.8 to 1.6 0.83 0.41 
    6 months 3.3 (N=39) 4.9 (N=38) 1.5 1.1 to 2.1 2.24 0.03 
       
These scales were not prioritized and hence are subject to missingness. 
a
All analyses were carried out using multiple imputation with 200 imputations (see Supplemental 
Material). 
b
Means are predicted for patients with average baseline outcome value, who are of younger age (≤65 
years), referred from St. Patrick’s Mental Health Services and have no previous experience of ECT.  
c
Analysis carried out on the log-scale, means back-transformed and effect estimates representing 
ratios (Bitemporal/Right unilateral).  
RUL=right unilateral ECT. MMSE=Mini-Mental State Examination. TMT=Trail Making Test (versions A 
and B). FCSRT= Free and Cued Selective Recall Test. CFT=Complex Figure Test. CSSES=Columbia ECT 
Subjective Side-Effects Schedule. 
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